Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told

By Bonnie Eslinger · June 13, 2023, 10:23 PM EDT

A retired Harvard Medical School health economics professor testified Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

3:19-cv-02573

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019